Nelarabine (nelarabine)
Multiple manufacturers; brand: Arranon by Novartis · Nucleoside Metabolic Inhibitor / Purine Analog
What is Nelarabine? Nelarabine (brand: Arranon) is a purine nucleoside analog used for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It is a prodrug that is converted to ara-GTP, which causes DNA strand breaks in T-cells.
About Nelarabine
| Brand Name | Nelarabine |
| Generic / INN | nelarabine |
| Drug Class | Nucleoside Metabolic Inhibitor / Purine Analog |
| Manufacturer | Multiple manufacturers; brand: Arranon by Novartis |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2005 |
FDA-Approved Uses for Nelarabine
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) — adults and pediatric patients after at least two prior chemotherapy regimens
- Relapsed or refractory T-cell lymphoblastic lymphoma (T-LBL) — adults and pediatric patients after at least two prior chemotherapy regimens
How Does Nelarabine Work?
Nelarabine is a prodrug that is demethylated to ara-G, then phosphorylated to ara-GTP. Ara-GTP accumulates preferentially in T-lymphoblasts (high deoxycytidine kinase activity) and incorporates into DNA, causing DNA strand breakage and cell death. The selective accumulation in T-cells gives nelarabine activity against T-cell leukemias and lymphomas.
Dosage & Administration
Adults: 1,500 mg/m² IV over 2 hours on days 1, 3, and 5, repeated every 21 days. Pediatric patients: 650 mg/m² IV over 1 hour daily for 5 consecutive days, repeated every 21 days.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
NEUROTOXICITY — can be severe and life-threatening (seizures, peripheral neuropathy, demyelination, ascending neuropathy similar to Guillain-Barré). Discontinue for grade 2 or greater neurologic toxicity. Hematologic toxicity. Embryo-fetal toxicity.
- Severe neurotoxicity — can be fatal (boxed warning implied)
- Ascending neuropathy / demyelination
- Seizures
- Severe hematologic toxicity
- Embryo-fetal toxicity
Common Side Effects
- Fatigue
- Peripheral neuropathy
- Nausea
- Diarrhea
- Headache
- Anemia
- Neutropenia
- Constipation
- Somnolence
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Store at room temperature 25°C (77°F). Store at 25°C (77°F).
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Nelarabine is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Nelarabine. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Nelarabine
Nelarabine (brand: Arranon) is used for relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adults and children after at least two prior chemotherapy regimens.
Severe neurotoxicity is the most serious risk — including peripheral neuropathy, seizures, and ascending neuropathy resembling Guillain-Barré syndrome. Patients and clinicians must monitor closely for neurologic symptoms throughout treatment.
Yes. Nelarabine's prodrug mechanism leads to selective accumulation in T-lymphoblasts, making it specifically active against T-cell malignancies. It is not used for B-cell ALL.
Nelarabine is covered by Medicare Part B and commercial insurance for the approved T-ALL/T-LBL indications with prior authorization.
Related Medications & Conditions
Related Medications
Vincristine · Cyclophosphamide · Methotrexate · Doxorubicin · Pegaspargase
Related Conditions
T-cell acute lymphoblastic leukemia (T-ALL) · T-cell lymphoblastic lymphoma (T-LBL) · Acute lymphoblastic leukemia (ALL)